免疫系统
癌症研究
免疫监视
下调和上调
趋化因子
肿瘤微环境
生物
细胞毒性T细胞
流式细胞术
主要组织相容性复合体
T细胞
免疫学
PD-L1
基因敲除
小发夹RNA
免疫疗法
CXCL16型
小干扰RNA
RNA干扰
基因剔除小鼠
先天免疫系统
质量细胞仪
自然杀伤性T细胞
肿瘤进展
CD8型
炎症
树突状细胞
白细胞介素12
细胞生物学
转录组
化学
信号转导
白细胞介素21
CCL5
细胞
癌细胞
干扰素γ
髓源性抑制细胞
作者
Yunyi Zhou,Ping Chen,Zhixue Wang,Liming Gui,Zhengheng Zheng,Wei‐Qiang Gao,Bin Ma
标识
DOI:10.1136/jitc-2025-012347
摘要
Background Major histocompatibility complex class I (MHC)-I loss is a prevalent mechanism for immune evasion and resistance to immunotherapy. However, how MHC-I loss shapes the tumor microenvironment and influences immune cell interactions, ultimately affecting tumor growth, remains largely unknown. Methods We established B2m knockout (MHC-I-deficient) tumor cells using CRISPR/Cas9 and evaluated their growth in subcutaneous and orthotopic mouse models. Immune profiling was performed using flow cytometry and single-cell RNA sequencing. Antibody-mediated cell depletion was used to assess the functional contributions of specific immune subsets. Chemokine expression was analyzed by bulk RNA sequencing, quantitative PCR, ELISA and western blotting, and its functional relevance was determined using knockout or overexpression in tumor cells implanted in vivo. Signaling pathways were interrogated using pharmacological inhibition, RNA interference and western blotting. Results MHC-I loss promoted tumor growth in MC38, AKR, and LLC1 models, but unexpectedly suppressed Hepa1-6 and orthotopic MYC;Trp53 −/− hepatocarcinoma growth. This differential effect correlated with changes in immune infiltrates. CD4 + T cells, natural killer (NK) cells, and macrophages were required for suppression of MHC-I-deficient Hepa1-6 tumors. CD4 + T cells were essential for recruiting NK cells and monocytes/macrophages and for inducing their tumoricidal phenotypes, including iNOS (inducible nitric oxide synthase) expression in macrophages. The differential infiltration of CD4 + T cells was driven by opposite regulation of CXCL16 on B2m knockout: upregulation in Hepa1-6 cells and downregulation in other models. CXCL16 exerted potent antitumor effects by recruiting CD4 + T cells. Mechanistically, B2M loss regulated CXCL16 via suppression of Akt in MC38 and AKR cells, but via activation of NF-κB in Hepa1-6 cells. Conclusion CXCL16-driven CD4 + T cells are central regulators of antitumor immunity against MHC-I-deficient tumors. The context-dependent regulation of CXCL16 by MHC-I loss determines the immune landscape and tumor outcome, highlighting a potential therapeutic avenue for targeting MHC-I-deficient cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI